Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: Strong Long who wrote (1604)	12/31/2015 6:49:50 PM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

Thanks for the cheers and optimism, SL. As disappointed as I have been with Vitaros as an investment vehicle, there is some good news here, and that would be in FDA approval along with advertising. EU sales would benefit as the US advertising and US use will drift across the Pond. Second and more important to us is that Apricus will have visibility to US investors. This is all contingent on FDA approval and Apricus hooking up with an outfit that is willing to truly launch Vitaros in the US market. That is why I somewhat favor Apricus getting a 15% stake and having Allergan run with the ball. Happy New Year from California's Heartland.